| Dr Navdeep Sood, MD | |
|
2201 N Broadwell Ave, Grand Island, NE 68803-2153 | |
| (308) 389-5134 | |
| (308) 389-5126 |
| Full Name | Dr Navdeep Sood |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 31 Years |
| Location | 2201 N Broadwell Ave, Grand Island, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043231830 | NPI | - | NPPES |
| 470378779-28 | Medicaid | NE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 21912 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial Community Hospital Mch & Health System | Blair, NE | Hospital |
| Thayer County Health Services | Hebron, NE | Hospital |
| Merrick Medical Center/litzenberg Memorial County Hospital | Central city, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mid-plains Center For Behavioral Healthcare Services, Inc. | 3375595853 | 6 |
| The Mary Lanning Memorial Hospital Association | 4587575550 | 117 |
News Archive
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.
In people with central nervous system (CNS) lymphoma, cancerous B cells-a type of white blood cell-accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.
Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
A restaurant workers' group and a Los Angeles community clinic have launched a unique cooperative to provide health coverage to a group of people excluded from federal health care reform - illegal immigrants. The pilot program, believed to be the first of its kind in the nation, offers preventive and primary care to low-wage, uninsured workers in the restaurant industry. Legal immigrants and other restaurant workers who don't meet the criteria or cannot afford coverage under the health care law are also eligible.
› Verified 9 days ago
| Entity Name | The Mary Lanning Memorial Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760530216 PECOS PAC ID: 4587575550 Enrollment ID: O20031105000492 |
News Archive
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.
In people with central nervous system (CNS) lymphoma, cancerous B cells-a type of white blood cell-accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.
Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
A restaurant workers' group and a Los Angeles community clinic have launched a unique cooperative to provide health coverage to a group of people excluded from federal health care reform - illegal immigrants. The pilot program, believed to be the first of its kind in the nation, offers preventive and primary care to low-wage, uninsured workers in the restaurant industry. Legal immigrants and other restaurant workers who don't meet the criteria or cannot afford coverage under the health care law are also eligible.
› Verified 9 days ago
| Entity Name | The Physician Network |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437184652 PECOS PAC ID: 3476453267 Enrollment ID: O20040128001100 |
News Archive
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.
In people with central nervous system (CNS) lymphoma, cancerous B cells-a type of white blood cell-accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.
Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
A restaurant workers' group and a Los Angeles community clinic have launched a unique cooperative to provide health coverage to a group of people excluded from federal health care reform - illegal immigrants. The pilot program, believed to be the first of its kind in the nation, offers preventive and primary care to low-wage, uninsured workers in the restaurant industry. Legal immigrants and other restaurant workers who don't meet the criteria or cannot afford coverage under the health care law are also eligible.
› Verified 9 days ago
| Entity Name | Alegent Creighton Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033288923 PECOS PAC ID: 1850285255 Enrollment ID: O20040326000802 |
News Archive
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.
In people with central nervous system (CNS) lymphoma, cancerous B cells-a type of white blood cell-accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.
Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
A restaurant workers' group and a Los Angeles community clinic have launched a unique cooperative to provide health coverage to a group of people excluded from federal health care reform - illegal immigrants. The pilot program, believed to be the first of its kind in the nation, offers preventive and primary care to low-wage, uninsured workers in the restaurant industry. Legal immigrants and other restaurant workers who don't meet the criteria or cannot afford coverage under the health care law are also eligible.
› Verified 9 days ago
| Entity Name | Thayer County Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326029984 PECOS PAC ID: 3577559145 Enrollment ID: O20041008000652 |
News Archive
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.
In people with central nervous system (CNS) lymphoma, cancerous B cells-a type of white blood cell-accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.
Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
A restaurant workers' group and a Los Angeles community clinic have launched a unique cooperative to provide health coverage to a group of people excluded from federal health care reform - illegal immigrants. The pilot program, believed to be the first of its kind in the nation, offers preventive and primary care to low-wage, uninsured workers in the restaurant industry. Legal immigrants and other restaurant workers who don't meet the criteria or cannot afford coverage under the health care law are also eligible.
› Verified 9 days ago
| Entity Name | Mid-plains Center For Behavioral Healthcare Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558303743 PECOS PAC ID: 3375595853 Enrollment ID: O20050211000893 |
News Archive
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.
In people with central nervous system (CNS) lymphoma, cancerous B cells-a type of white blood cell-accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.
Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
A restaurant workers' group and a Los Angeles community clinic have launched a unique cooperative to provide health coverage to a group of people excluded from federal health care reform - illegal immigrants. The pilot program, believed to be the first of its kind in the nation, offers preventive and primary care to low-wage, uninsured workers in the restaurant industry. Legal immigrants and other restaurant workers who don't meet the criteria or cannot afford coverage under the health care law are also eligible.
› Verified 9 days ago
| Entity Name | Thayer County Memorial Hospital |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1326029984 PECOS PAC ID: 3577559145 Enrollment ID: O20061104000293 |
News Archive
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.
In people with central nervous system (CNS) lymphoma, cancerous B cells-a type of white blood cell-accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.
Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
A restaurant workers' group and a Los Angeles community clinic have launched a unique cooperative to provide health coverage to a group of people excluded from federal health care reform - illegal immigrants. The pilot program, believed to be the first of its kind in the nation, offers preventive and primary care to low-wage, uninsured workers in the restaurant industry. Legal immigrants and other restaurant workers who don't meet the criteria or cannot afford coverage under the health care law are also eligible.
› Verified 9 days ago
| Entity Name | Phelps Memorial Health Center |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1629035936 PECOS PAC ID: 9931011947 Enrollment ID: O20071129000753 |
News Archive
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.
In people with central nervous system (CNS) lymphoma, cancerous B cells-a type of white blood cell-accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.
Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
A restaurant workers' group and a Los Angeles community clinic have launched a unique cooperative to provide health coverage to a group of people excluded from federal health care reform - illegal immigrants. The pilot program, believed to be the first of its kind in the nation, offers preventive and primary care to low-wage, uninsured workers in the restaurant industry. Legal immigrants and other restaurant workers who don't meet the criteria or cannot afford coverage under the health care law are also eligible.
› Verified 9 days ago
| Entity Name | Phelps Memorial Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871528851 PECOS PAC ID: 9931011947 Enrollment ID: O20080603000111 |
News Archive
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.
In people with central nervous system (CNS) lymphoma, cancerous B cells-a type of white blood cell-accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.
Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
A restaurant workers' group and a Los Angeles community clinic have launched a unique cooperative to provide health coverage to a group of people excluded from federal health care reform - illegal immigrants. The pilot program, believed to be the first of its kind in the nation, offers preventive and primary care to low-wage, uninsured workers in the restaurant industry. Legal immigrants and other restaurant workers who don't meet the criteria or cannot afford coverage under the health care law are also eligible.
› Verified 9 days ago
| Entity Name | Span Psychiatry Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659909117 PECOS PAC ID: 9830528157 Enrollment ID: O20200407001720 |
News Archive
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.
In people with central nervous system (CNS) lymphoma, cancerous B cells-a type of white blood cell-accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.
Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
A restaurant workers' group and a Los Angeles community clinic have launched a unique cooperative to provide health coverage to a group of people excluded from federal health care reform - illegal immigrants. The pilot program, believed to be the first of its kind in the nation, offers preventive and primary care to low-wage, uninsured workers in the restaurant industry. Legal immigrants and other restaurant workers who don't meet the criteria or cannot afford coverage under the health care law are also eligible.
› Verified 9 days ago
| Entity Name | Evizzit Of Iowa Psychiatry Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740841188 PECOS PAC ID: 2860825924 Enrollment ID: O20200522000470 |
News Archive
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.
In people with central nervous system (CNS) lymphoma, cancerous B cells-a type of white blood cell-accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.
Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
A restaurant workers' group and a Los Angeles community clinic have launched a unique cooperative to provide health coverage to a group of people excluded from federal health care reform - illegal immigrants. The pilot program, believed to be the first of its kind in the nation, offers preventive and primary care to low-wage, uninsured workers in the restaurant industry. Legal immigrants and other restaurant workers who don't meet the criteria or cannot afford coverage under the health care law are also eligible.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Navdeep Sood, MD 4110 Hartford St, Grand Island, NE 68803-2263 Ph: (308) 389-5134 | Dr Navdeep Sood, MD 2201 N Broadwell Ave, Grand Island, NE 68803-2153 Ph: (308) 389-5134 |
News Archive
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4.
In people with central nervous system (CNS) lymphoma, cancerous B cells-a type of white blood cell-accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.
Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.
OncoGenex Pharmaceuticals, Inc. today announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer.
A restaurant workers' group and a Los Angeles community clinic have launched a unique cooperative to provide health coverage to a group of people excluded from federal health care reform - illegal immigrants. The pilot program, believed to be the first of its kind in the nation, offers preventive and primary care to low-wage, uninsured workers in the restaurant industry. Legal immigrants and other restaurant workers who don't meet the criteria or cannot afford coverage under the health care law are also eligible.
› Verified 9 days ago
Ganga Ram Sharma, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: Veterans Administration Medical Center, 2201 North Broadwell Ave, Grand Island, NE 68803 Phone: 308-382-3660 Fax: 308-389-5126 | |
Dr. Joel Orosa Paraiso, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 403 Lexington Cir, Grand Island, NE 68803 Phone: 402-773-0115 Fax: 402-773-0119 | |
Adeolu Oluwaseun Morawo, MBCHB, MS. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 908 N Howard Ave Ste 105, Grand Island, NE 68803 Phone: 308-398-8900 Fax: 308-398-8901 | |
Balachandran Wariyar, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2201 N Broadwell Ave, Grand Island, NE 68803 Phone: 402-697-1481 |